Cargando…
Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release
Exenatide extended-release was recently developed as an antidiabetic drug; it acts as a glucagon-like peptide-1 receptor agonist. A 54-year-old male visited our clinic complaining of a subcutaneous tender nodule on his left thigh that had developed over the course of 1 week. The patient had received...
Autores principales: | Ko, Jung-Woo, Park, Kyung-Duck, Lee, Young, Lee, Jeung-Hoon, Hong, Dong-Kyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Dermatological Association; The Korean Society for Investigative Dermatology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992610/ https://www.ncbi.nlm.nih.gov/pubmed/33911742 http://dx.doi.org/10.5021/ad.2020.32.3.230 |
Ejemplares similares
-
Factitial panniculitis secondary to injected subcutaneous elemental mercury
por: Vinupriya, Sakkaravarthi, et al.
Publicado: (2022) -
The coexistence of lupus erythematosus panniculitis and subcutaneous panniculitis-like T-cell lymphoma in the same patient
por: Wu, Xinyu, et al.
Publicado: (2018) -
Input Estimation for Extended-Release Formulations Exemplified with Exenatide
por: Trägårdh, Magnus, et al.
Publicado: (2017) -
Eosinophilic Panniculitis Associated With COVID-19()
por: Leis-Dosil, V.M., et al.
Publicado: (2020) -
Subcutaneous Panniculitis-Like T-Cell Lymphoma of the Breast
por: Jeong, Seo In, et al.
Publicado: (2013)